Morepen Laboratories Ltd has received clearance from CDSCO to conduct Bioequivalence studies for Resmetirom, a new drug for fatty liver disease, marking a significant step toward its global launch on April 29, 2025.
AI Assistant
Morepen Laboratories Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.